Global Point of Care Testing for Hepatitis B Virus Market Size to Grow at 6.5% CAGR from 2025 to 2030

Global Point of Care Testing for Hepatitis B Virus Market Size (2025 –2030)

As per our research report, the global Point of Care Testing for Hepatitis B Virus Market size is estimated to be growing at a CAGR of 6.5% from 2025 to 2030. 

Hepatitis B virus (HBV) Point of Care Testing (POCT) is a quick diagnostic test that patients can do themselves on-site without the need for specialized lab equipment or highly qualified staff. It's like going to your doctor's office for a quick test for strep throat instead of a lab test. POCT can be highly helpful because it yields results faster, cheaper, and more conveniently for both patients and healthcare practitioners. However, 90% of those with hepatitis B are surprisingly ignorant of their condition. This is a significant problem because, despite the fact that hepatitis B can be lethal, many people do not have easy access to the blood tests needed to screen for it.

About 292 million people worldwide suffer from the prevalent viral infection known as the hepatitis B virus (HBV). Early detection and therapy are critical to halting the progression of the disease. If neglected, it can lead to serious conditions like cirrhosis and liver cancer. Because of the growing number of cases, there is a greater need for HBV testing and surveillance. New diagnostic methods, such as nucleic acid testing (NAT) and point-of-care testing (POCT), have made it easier, faster, and more accurate to diagnose HBV infections. This suggests that we can identify and treat HBV with greater precision. Initiatives to combat HBV and provide access to care and screening have been launched by governments worldwide.

The presence of the hepatitis B virus (HBV) can be determined using a variety of assays. To find out if an infection is still present, one test, called the HBsAg test, looks for a piece of the virus in the blood. The anti-HBc test is another that searches for antibodies that indicate a past or present illness. The anti-HBs test can also be used to determine whether a person has gotten the vaccination or is immune to HBV. The viral load test quantifies the amount of virus in the blood, whereas the HBeAg test indicates whether the virus is actively spreading. Liver damage can also be found by liver function tests like AST and ALT.

The COVID-19 pandemic has had a negative effect on the global market for point-of-care testing (POCT) for the hepatitis B virus (HBV). Lockdowns, travel restrictions, and overburdened healthcare systems have made it more difficult for people to access HBV testing and treatment. There is a greater likelihood that HBV may spread and result in serious health problems as a result of these variables, which include missing or delayed diagnosis, interrupted treatments, and a lack of prophylactic measures like immunization. The market for HBV POCT devices, which are now more costly and less accessible, has shrunk as a result of these challenges. Furthermore, compared to COVID-19, viral hepatitis is not as well-known among patients, medical professionals, and policymakers. Innovation in HBV POCT devices is required to address these problems.

The market for Hepatitis B virus (HBV) Point of Care Testing (POCT) has several opportunities for growth and improvement. Home-based testing is becoming more popular since it gives patients more convenience and privacy. Improvements in cassette and card technologies have made testing more precise and comprehensive. Integrating HBV POCT devices with COVID-19 testing equipment helps expedite procedures. Early detection and monitoring are important objectives that POCT devices can help achieve. Underdeveloped areas with poor access to healthcare offer unexplored prospects for market growth. In general, the HBV POCT market offers opportunities for improvement, growth, and patient care.

KEY MARKET INSIGHTS:  

• Based on market segmentation by Application, the cassette and card industries are thriving because they provide several advantages over strips. With cassettes or cards, several parameters can be checked at once, providing a more comprehensive testing experience. The accuracy and reliability of test results are increased by their regular integration of controls and sample-collection instruments. Furthermore, cassettes and cards can detect HBV infection at lower concentrations and provide more reliable results than strips since they often have higher sensitivity and specificity. They are therefore ideal for early identification and monitoring of HBV infections. However, strips continue to command the largest share of the market. They are easier to use in environments with limited resources because they are less complicated and more reasonably priced than cassettes or cards.
• Based on market segmentation by End-User, the home care sector is expanding rapidly due to the increasing need for decentralized healthcare and possibilities for testing that may be done at home. Instead of seeing the doctor frequently, patients would want to conveniently and privately check their HBV status at home. In the meantime, hospitals continue to dominate the HBV testing industry. Due to their extensive patient populations and range of medical services, hospitals are crucial for HBV testing. To provide accurate and timely results, they often do point-of-care testing, utilizing specialized labs and skilled staff. Hospitals are also equipped to handle complex cases and provide patients with HBV with comprehensive care.
• Based on market segmentation by Region, due to the region's advanced healthcare system, high healthcare spending, and concentration of significant industry participants, North America has the highest prevalence of HBV point-of-care testing (POCT). The increasing prevalence of HBV in the region is driving the need for POCT devices. North America's market dominance is partly a result of the government's supportive reimbursement policies and encouragement of early HBV identification. The European market for HBV POCT is growing rapidly because of the continent's advanced healthcare system and high level of HBV awareness. The region places a high premium on preventative healthcare and the early detection of infectious disorders like HBV. Europe's strong position in the sector is a result of both the presence of major market players and modern POCT technology.
• Companies playing a leading role in the Global Point of Care Testing for Hepatitis B Virus Market profiled in this report are – Abbott Laboratories, Roche Diagnostics, bioMérieux SA, Danaher Corporation, Qiagen N.V., Siemens Healthineers AG, SD Biosensor Inc., Alere Inc., Biomedicglobal, and Meridian Bioscience Inc.

By Product Type

• Cassettes/Cards
• Strips

By End Users

• Hospitals
• Diagnostic Centers
• Clinics
• Home Care

By Region 

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Request sample of this report @ https://virtuemarketresearch.com/report/point-of-care-testing-for-hepatitis-b-virus-market/request-sample